ALEXION PHARMACEUTICALS INC. overview
ALEXION PHARMACEUTICALS INC. > News
Business Wire published a news.
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
•
•
Business Wire •
Stocks •
More ALEXION PHARMACEUTICALS INC. news...
Thank you